San Diego's Alterome Therapeutics raised a $132M Series B today for its precision oncology platform

blonca9
Apr 3, 2024
1 min read

Co-Founder and CEO Eric Murphy describes what it was like raising the money in this environment, and delves into Alterome's programs, including AKT1 E17K and KRAS.

Recent Posts

See All

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

AI news: Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

San Diego's Alterome Therapeutics raised a $132M Series B today for its precision oncology platform

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight